Search page

A promising alternative to monoclonal antibody therapy for the treatment of severe Asthma – a Capsid virus-like particle-based vaccine displaying AI-generated TSLP antigens

Baseline Type 2 Biomarkers and Mucus Plug Response in Patients With Uncontrolled Moderate-to-Severe Asthma Treated With Dupilumab in the VESTIGE Study

Basophil FceRI expression-A management tool in anti-IgE treatment of allergic asthma

Benralizumab as treatment in a patient with Near-Fatal Asthma exacerbation

Beyond the future – perspectives in the diagnosis and treatment of allergy and asthma

Biologics have Solved the Problem of Type 2 Asthma

Biomarker-guided approach for treatment of preschool asthma

Characteristics of Severe type 2 Asthma Patients in China: A Retrospective Observational Study

Characteristics of patients with severe asthma undergoing biological treatment at a reference center

Characteristics of severe eosinophilic asthma in childhood-onset and adult-onset asthma in U-BIOPRED

Characterization of Patients With Asthma Initiating Dupilumab Treatment in a Real-World Setting: The RAPID Registry

Clinical effects of dupilumab in patients with rhinosinusitis, nasal polyposis, and severe uncontrolled asthma with t2 phenotype, after 12 months of treatment

Comparison of the efficacy of subcutaneous and sublingual immunotherapy for the treatment of allergic asthma in children

Cytometric detection of Der p 1 and Der p 2 binding to Basophils (CytoBas) enables precise determination of house dust mite sensitization in patients with asthma and allergic rhinitis

Dissecting the molecular mechanisms underlying TSLP-driven non-type 2 inflammatory responses in severe asthma

Distribution of IL-1β Expression in Asthma Patients and Comparison of Therapeutic Efficacy of Different Administration Routes of IL-1β Neutralizing Antibody in a Mouse Model of Asthma

Dupilumab Improves Lung Function and Reduces Exacerbation Frequency and IgE Levels in Patients with Asthma and Allergic Bronchopulmonary Aspergillosis (Phase 2 LIBERTY ABPA AIRED Study)

Dupilumab Reduces FeNO levels and Exacerbations and Improves Asthma Control with Inhaled Corticosteroid Withdrawal: a Phase 2 Study

Dupilumab Reduces Seasonal Exacerbation Rates in Children With Type 2 Asthma With or Without Evidence of Allergy

Dupilumab Treatment Reduces IgE Levels in Patients Aged 2 to 17 Years With Atopic Dermatitis, Asthma, and Eosinophilic Esophagitis

Dupilumab Treatment is Associated with Clinical Improvement and a Shift towards a health-associated Nasal Passage Microbiota in Diffuse Type 2 Chronic Rhinosinusitis

Dupilumab treatment effectively reduces nasal type 2 cytokine production following acetylsalicylic acid provocation in N-ERD patients

Effectiveness of allergy immunotherapy on asthma medication use and asthma exacerbations: Results from the Real world Evidence of aLlergy immunotherapY (RELY) study

Efficacy of Rilzabrutinib on Asthma Control: Results From a Double-Blind Placebo-Controlled Phase 2 Study

Efficacy of Rilzabrutinib on Asthma Quality of Life: Results From a Double-Blind Placebo-Controlled Phase 2 Study

Elevating patient treatment outcomes in Severe Asthma

Elevating patient treatment outcomes in Severe Asthma & comorbid CRSwNP

Environmental impact of asthma treatment

Eosinophilia over dupilumab treatment in asthma patients: a multicentric retrospective study

Evaluation of Asthma Course in Patients Hospitalized in Pediatric Intensive Care Unit Due to Severe Asthma Exacerbation

Evaluation of the concordance of definitions of Asthma Remission according to international guidelines in a cohort of patients treated with monoclonal antibodies for severe asthma

Future Treatment Landscape with Omalizumab Biosimilar in Asthma

GSK – Elevating patient treatment outcomes in severe asthma and CRSwNP

Health Care Situation in the Treatment of Uncontrolled GINA 4/5 Asthma Patients in Germany: 2019 vs. 2022

Immune skewing and the impact on treatment response in adult asthma

Impact of liquid sublingual immunotherapy on asthma worsening prevention: GINA treatment stepping up results from the real-world EfficAPSI study

Improvement in Lung Function with Rademikibart in Eosinophilic Driven, Type 2 Asthma

Increase in airway resistance and respiratory bronchial reactivity is accompanied by cellular and antibody Type 2 immune response in a mouse model of asthma induced by Der p 23 allergen

Indirect case matched comparison of dupilumab versus benralizumab on mannitol airway hyperresponsiveness in type 2 high severe asthma

Inhibition of the Interleukin Cytokines using novel Peptide Inhibitors for Allergy and Asthma Treatment

Involvement of Janus kinase (JAK)-dependent Bcl-xL overexpression in steroid resistance of group 2 innate lymphoid cells (ILC2s) in asthma

KalVista Pharmaceuticals – Closing Gaps in HAE Management: Addressing Treatment Delays in On-Demand Treatment

Lichen Planus induced by treatment of severe eosinophilic asthma with biological therapy

Lichen planus following dupilumab treatment in patients with severe asthma and nasal sinus polyposis

Lung Function Improvement is Associated With Better Asthma Control in Adolescents and Adults Aged 12 Years and Older With Moderate-to-Severe Type 2 Asthma: A Post Hoc Analysis of QUEST

Lung Function Responder Rates in the VOYAGE study in Children with Moderate-to-Severe Type 2 Asthma Receiving Dupilumab at Week 52

Lung function and exacerbations by different type 2 inflammation criteria in a general asthma population

Lymphocyte profile and asthma control during the treatment with benralizumab in real life

Monitoring for early warning signs of asthma attacks and response to treatment with oral corticosteroids using the Albus Home contactless monitoring system

Nasal transcriptomics as a biomarker for ICS/LABA treatment in paediatric asthma in the PUFFIN study

New strategies in the treatment of severe asthma

Prevalence and clinical characteristics of adult asthma patients with different phenotype across GINA step 1 to 5 asthma

Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic Driven, Type 2 Asthma

Self-reported asthma symptoms and asthma medication usage in patients with possible asthma: A MASK-air® real-world study

Self-reported treatment preferences of patients switching from prior prophylactic therapies to donidalorsen for the treatment of hereditary angioedema: Results from the phase 3 OASISplus study

Serum cytokine profiles of pediatric normal weight asthma and overweight/obese asthma and their correlation with pulmonary function indices

Severe asthma and sleep disorders: a Severe Asthma Network Italy (SANI) analysis

Successful treatment of severe asthma after switch of biologics. A case report

Sustained reduction in Severe Asthma Exacerbations and Hospitalisations in the 12 months after Alpine Altitude Climate Treatment

Sympout study: Need of medication for symptom control in patients with rhinitis and/or bronchial asthma due to house dust mites or pollens in treatment with sublingual immunotherapy in a standardized liquid formulation in TBU/ml

Systematic literature review and adjusted indirect treatment comparisons of 2 allergen immunotherapy treatments for grass pollen–induced allergic rhinitis

Targeted drug-induced apoptosis in key cellular mediators of allergic asthma as a new treatment strategy

The Use of Long-acting Muscarinic Antagonist (LAMA) in the Treatment of Asthma: A Tertiary Asthma Center Experience

The effect of tezepelumab treatment on the incidence of asthma exacerbations co-occurring with acute respiratory illnesses attributed to infections: results from a pooled analysis of the PATHWAY and NAVIGATOR studies

The m6A demethylase FTO mediates type 2 inflammation in asthma by regulating STAT6 mRNA stability

The relationship between asthma duration and biomarker profiles in severe asthma

The treatment of eosinophilic asthma with mepolizumab and benralizumab: relative effectiveness

The triple type 2 signature is associated to asthma severity and comorbidity with CRS

Toward Optimal disease control: impact of maintenance inhaler therapy and device transition in severe asthma patients undergoing monoclonal antibody treatment

Treatment of different asthma endotypes

Treatment of severe asthma (update)

Treatment with Barzolvolimab Leads to Sustained Improvement in Angioedema in Chronic Spontaneous Urticaria (CSU) patients: Results from 52 Weeks of Treatment

Worse asthma control in patients with asthma and respiratory allergies in the CAPTURE study: Rationale for developing the RespiratoryAllergyOptimiser

Asthma control, lung function, and quality of life in pediatric patients with severe asthma undergoing biological treatment

Characteristics and Asthma Control Status of Severe Asthma Patients in the Korean Severe Asthma Registry-2 (KoSAR-2)

Characteristics of asthma phenotypes: Does coexistence of allergic and eosinophilic asthma increase asthma severity?

Decoding Asthma Therapies: Transcriptomic differences between benralizumab and mepolizumab treatment in patients with severe eosinophilic asthma

Dupilumab Reduces Exacerbations and Improves Asthma Control in Children With Moderate-to-Severe Type 2 Asthma, Regardless of Asthma Duration

Inhaled Corticosteroid Reduction Effects on Asthma Outcomes after Three Years of Benralizumab Treatment in Severe Asthma Patients

Investigation Of Treatment Responses And Clinical Characteristics Of Patients With The Late-Onset Asthma Phenotype Under Biological Treatment

Mepolizumab Improves and Sustains Asthma Control and Lung Function in Patients with Severe Asthma Independent of Baseline Blood Eosinophil Count in the Real World: Results from REALITI-A at 2 Years

Mepolizumab provides sustained clinical benefits in patients with severe asthma regardless of age of asthma onset: Real-world data from the REALITI-A study at 2 years

Patients with severe eosinophilic asthma starting anti-IL5 treatment after 2018 have better preserved lung function compared to the patients who started treatment earlier

Pollution particles and their role on asthma exacerbations of adult patients who visited emergency departments in 2 university hospitals of Madrid city: A 2 year comparison using Big-Data Analysis

Real-world change in asthma symptom control and oral corticosteroid use in patients with severe asthma treated with mepolizumab stratified by atopic status: Post hoc analysis of REALITI-A at 2 years

Registry on Severe Asthma with and without biological treatment in Spain: Results of a 2 year follow-up of AlergoDATA

The Use of Long-Acting Muscarinic Antagonist in the Treatment of Asthma: A Latin-American 2 Specialized Asthma Center Experience

Use of the AllergyVax Doctor app to evaluate the correlation between adherence to treatment and control of rhinitis and asthma in patients during treatment with SLIT

Welcome

Only match titles

What are you looking for?

Knowledge Hub

Website

Only match titles

What are you looking for?

Knowledge Hub

Sponsored Symposia

Event Resources

Task Forces

Position Papers

Covid-19

Courses

Website

Sessions